Errata, Volume 24, 2004
EKYUHO HAN, C BUTLER, H ZHANG, JM SEVERIN… - ar.iiarjournals.org
Volume 25, Number 1A, pages 101-106: In all of the experiments in which flavopiridol was
used, the concentrations were in nanomolar and not micromolar. The concentrations of all of …
used, the concentrations were in nanomolar and not micromolar. The concentrations of all of …
Flavopiridol. National Cancer Institute.
HK Wang - Current opinion in investigational drugs (London …, 2001 - europepmc.org
Flavopiridol is a synthetic flavonoid inhibitor of cyclin-dependent kinases, which is under
development by Aventis Pharma (formerly Hoechst Marion Roussel) and the National …
development by Aventis Pharma (formerly Hoechst Marion Roussel) and the National …
Development and validation of a sensitive liquid chromatography/mass spectrometry method for quantitation of flavopiridol in plasma enables accurate estimation of …
MA Phelps, DM Rozewski, JS Johnston… - … of Chromatography B, 2008 - Elsevier
A high-performance liquid chromatographic assay with tandem mass spectrometric
detection was developed and validated for quantitation of the broad spectrum kinase …
detection was developed and validated for quantitation of the broad spectrum kinase …
A high‐performance liquid chromatography method using ultraviolet detection for the quantitation of flavopiridol from human plasma
S Zhai, E Sausville, WD Figg - Biomedical Chromatography, 2002 - Wiley Online Library
Flavopiridol is an inhibitor of cyclin‐dependent kinase, a key regulator of cell cycle, and is
currently under clinical trials. We developed and validated an HPLC assay method for the …
currently under clinical trials. We developed and validated an HPLC assay method for the …
Flavopiridol Hoechst AG.
MJ Zvelebil - Idrugs: the Investigational Drugs Journal, 1998 - europepmc.org
Hoechst is developing flavopiridol, a synthetic flavonoid based on an extract from an Indian
plant, for the potential treatment of cancer. Flavopiridol, a cyclin-dependent kinase inhibitor …
plant, for the potential treatment of cancer. Flavopiridol, a cyclin-dependent kinase inhibitor …
Clinical pharmacology of flavopiridol following a 72-hour continuous infusion
MA Rudek, KS Bauer Jr, RM Lush III… - Annals of …, 2003 - journals.sagepub.com
Background Flavopiridol, a novel flavone derivative, inhibits cyclin-dependent kinase-1. We
initiated a Phase I trial in patients with refractory solid tumors to determine the maximum …
initiated a Phase I trial in patients with refractory solid tumors to determine the maximum …
Determination of flavopiridol (L86 8275; NSC 649890) in human plasma by reversed-phase liquid chromatography with electrochemical detection
SF Stinson, K Hill, TJ Siford, LR Phillips… - Cancer chemotherapy and …, 1998 - Springer
Purpose: Flavopiridol is a flavone which inhibits several cyclin-dependent kinases, and
exhibits potent growth-inhibitory activity against a number of human tumor cell lines both in …
exhibits potent growth-inhibitory activity against a number of human tumor cell lines both in …
Determination of flavopiridol (L 86 8275) in rat serum using ion-pair reversed-phase high-performance liquid chromatography
PK Inamdar, RD Yeole - Drug development and industrial …, 1997 - Taylor & Francis
A specific, sensitive, and simple high-performance liquid chromatographic method has been
developed for assaying flavopiridol in rat serum for preliminary bioavailability and …
developed for assaying flavopiridol in rat serum for preliminary bioavailability and …
Parenteral formulation of flavopiridol (NSC-649890)
RM Dannenfelser, Y Surakitbanharn… - PDA Journal of …, 1996 - journal.pda.org
Flavopiridol [5, 7-dihydroxy-8-(4-N-methyl-2-hydroxypyridyl)-6′-chloroflavone
hydrochloride] is a flavonoid with weak electrolyte properties and an intrinsic aqueous …
hydrochloride] is a flavonoid with weak electrolyte properties and an intrinsic aqueous …
A novel liposomal formulation of flavopiridol
Flavopiridol has shown promising activities in hematologic and solid tumor models, as well
as in clinical trials in chronic lymphocytic leukemia patients. Flavopiridol has relatively low …
as in clinical trials in chronic lymphocytic leukemia patients. Flavopiridol has relatively low …